Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 148 articles: HTML format Text format

Single Articles

June 2018
1. SHAH D, Wyatt D, Baker A, Simms P, et al
   Inhibition of HER2 Enriches for Jagged1-dependent Breast Cancer Stem Cells: Role for Membrane Jagged1.
   Clin Cancer Res. 2018 Jun 12. pii: 1078-0432.CCR-17-1952.
   PubMed     Text format     Abstract available
   
   
   
2. BARRY P, Vatsiou A, Spiteri I, Nichol D, et al
   The spatio-temporal evolution of lymph node spread in early breast cancer.
   Clin Cancer Res. 2018 Jun 11. pii: 1078-0432.CCR-17-3374.
   PubMed     Text format     Abstract available
   
   
   
3. BARDIA A, Hurvitz S
   Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances.
   Clin Cancer Res. 2018 Jun 8. pii: 1078-0432.CCR-18-0162.
   PubMed     Text format     Abstract available
   
   
   May 2018
4. UNNI N, Sudhan DR, Arteaga CL
   Neratinib: Inching up on the cure rate of HER2+ breast cancer?
   Clin Cancer Res. 2018 May 25. pii: 1078-0432.CCR-18-1114.
   PubMed     Text format     Abstract available
   
   
   
5. ANURAG M, Punturi N, Hoog J, Bainbridge MN, et al
   Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers.
   Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-17-3702.
   PubMed     Text format     Abstract available
   
   
   
6. DICKLER MN, Saura C, Richards D, Krop I, et al
   Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
   Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-18-0613.
   PubMed     Text format     Abstract available
   
   
   
7. BAYRAKTAR R, Ivan C, Bayraktar E, Kanlikilicer P, et al
   Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion.
   Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-17-1959.
   PubMed     Text format     Abstract available
   
   
   April 2018
8. SPRING L, Bardia A
   Cycling Towards Progress: Ribociclib, CDK 4/6 inhibitor for Breast Cancer.
   Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0463.
   PubMed     Text format     Abstract available
   
   
   
9. VISSER LL, Elshof LE, Schaapveld M, Van de Vijver K, et al
   Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ - A nested case-control study.
   Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0201.
   PubMed     Text format     Abstract available
   
   
   
10. GOODMAN CR, Seagle BL, Kocherginsky M, Donnelly ED, et al
    21-gene recurrence score assay predicts benefit of post-mastectomy radiotherapy in T1-2 N1 breast cancer.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3169.
    PubMed     Text format     Abstract available
    
    
    
11. POST AEM, Smid M, Nagelkerke A, Martens JWM, et al
    Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-2551.
    PubMed     Text format     Abstract available
    
    
    
12. WEST DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, et al
    Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer.
    Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2793.
    PubMed     Text format     Abstract available
    
    
    
13. LOIBL S, Weber K, Huober J, Krappmann K, et al
    Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-2947.
    PubMed     Text format     Abstract available
    
    
    
14. RUGO HS, Cortes J, Awada A, O'Shaughnessey J, et al
    Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3059.
    PubMed     Text format     Abstract available
    
    
    March 2018
15. AFGHAHI A, Purington N, Han SS, Desai M, et al
    Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    Clin Cancer Res. 2018 Mar 26. pii: 1078-0432.CCR-17-1323.
    PubMed     Text format     Abstract available
    
    
    
16. WARD E, Vareslija D, Charmsaz S, Fagan A, et al
    Epigenome-wide SRC-1 mediated gene silencing represses cellular differentiation in advanced breast cancer.
    Clin Cancer Res. 2018 Mar 22. pii: 1078-0432.CCR-17-2615.
    PubMed     Text format     Abstract available
    
    
    
17. RUGO HS, Delord JP, Im SA, Ott PA, et al
    Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen ReceptorPositive/Human Epidermal Growth Factor Receptor 2Negative Advanced Breast Cancer.
    Clin Cancer Res. 2018 Mar 20. pii: 1078-0432.CCR-17-3452.
    PubMed     Text format     Abstract available
    
    
    
18. CHUMSRI S, Sperinde J, Liu H, Gligorov J, et al
    High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-1864.
    PubMed     Text format     Abstract available
    
    
    
19. FILIPITS M, Dafni U, Gnant M, Polydoropoulou V, et al
    Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-3473.
    PubMed     Text format     Abstract available
    
    
    
20. SINGH H, Walker AJ, Amiri-Kordestani L, Cheng J, et al
    U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer.
    Clin Cancer Res. 2018 Mar 9. pii: 1078-0432.CCR-17-3628.
    PubMed     Text format     Abstract available
    
    
    
21. RICCIARDELLI C, Bianco-Miotto T, Jindal S, Butler LM, et al
    The Magnitude of Androgen Receptor Positivity in Breast Cancer is Critical for Reliable Prediction of Disease Outcome.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-1199.
    PubMed     Text format     Abstract available
    
    
    
22. LIU L, Yang L, Yan W, Zhai J, et al
    Chemotherapy induces breast cancer stemness in association with dysregulated monocytosis.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-2545.
    PubMed     Text format     Abstract available
    
    
    February 2018
23. FORMENTI SC, Lee P, Adams S, Goldberg JD, et al
    Focal Irradiation And Systemic Transforming Growth Factor beta Blockade in Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-3322.
    PubMed     Text format     Abstract available
    
    
    
24. NEVEN P, Jongen L, Lintermans A, Van Asten K, et al
    Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial.
    Clin Cancer Res. 2018 Feb 19. pii: 1078-0432.CCR-17-3028.
    PubMed     Text format     Abstract available
    
    
    
25. KARAPANAGIOTIS S, Pharoah PDP, Jackson CH, Newcombe PJ, et al
    Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-3542.
    PubMed     Text format     Abstract available
    
    
    
26. HAMILTON EP, Patel MR, Armstrong AC, Baird RD, et al
    A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-17-3102.
    PubMed     Text format     Abstract available
    
    
    
27. SHAH A, Bloomquist E, Tang S, Fu W, et al
    FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-2369.
    PubMed     Text format     Abstract available
    
    
    
28. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Text format     Abstract available
    
    
    
29. MARTINS CD, Da Pieve C, Burley TA, Smith R, et al
    HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-based PET Imaging.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2754.
    PubMed     Text format     Abstract available
    
    
    
30. GONG C, Man EP, Tsoi H, Lee TK, et al
    BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen Resistant Breast Cancer.
    Clin Cancer Res. 2018 Feb 2. pii: 1078-0432.CCR-17-2259.
    PubMed     Text format     Abstract available
    
    
    January 2018
31. MISHRA RR, Belder N, Ansari SA, Kayhan M, et al
    Re-activation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer.
    Clin Cancer Res. 2018 Jan 31. pii: 1078-0432.CCR-17-2776.
    PubMed     Text format     Abstract available
    
    
    
32. ECHAVARRIA I, Lopez-Tarruella S, Picornell AC, Garcia-Saenz JA, et al
    Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
    Clin Cancer Res. 2018 Jan 29. pii: 1078-0432.CCR-17-1912.
    PubMed     Text format     Abstract available
    
    
    
33. PIGGOTT L, da Silva AM, Robinson T, Santiago-Gomez A, et al
    Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP.
    Clin Cancer Res. 2018 Jan 23. pii: 1078-0432.CCR-17-1381.
    PubMed     Text format     Abstract available
    
    
    
34. YANG X, Pan Y, Qiu Z, Du Z, et al
    RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.
    Clin Cancer Res. 2018 Jan 11. pii: 1078-0432.CCR-17-2242.
    PubMed     Text format     Abstract available
    
    
    
35. MAGBANUA MJM, Rugo HS, Wolfe DM, Hauranieh L, et al
    Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.
    Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2312.
    PubMed     Text format     Abstract available
    
    
    
36. DAVILA-GONZALEZ D, Choi DS, Rosato RR, Granados-Principal S, et al
    Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple negative breast cancer.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1437.
    PubMed     Text format     Abstract available
    
    
    December 2017
37. MASTORAKI S, Strati A, Tzanikou E, Chimonidou M, et al
    ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment.
    Clin Cancer Res. 2017 Dec 28. pii: 1078-0432.CCR-17-1181.
    PubMed     Text format     Abstract available
    
    
    
38. ZHAO EY, Shen Y, Pleasance E, Kasaian K, et al
    Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    Clin Cancer Res. 2017;23:7521-7530.
    PubMed     Text format     Abstract available
    
    
    November 2017
39. LENZ G, Hamilton A, Geng S, Hong T, et al
    t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0824.
    PubMed     Text format     Abstract available
    
    
    
40. ROSSI G, Mu Z, Rademaker A, Austin L, et al
    Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2092.
    PubMed     Text format     Abstract available
    
    
    
41. AUSHEV VN, Lee E, Zhu J, Gopalakrishnan K, et al
    Novel predictors of breast cancer survival derived from miRNA activity analysis.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0996.2017.
    PubMed     Text format     Abstract available
    
    
    
42. EVANS KW, Yuca E, Akcakanat A, Scott SM, et al
    A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Clin Cancer Res. 2017;23:6468-6477.
    PubMed     Text format     Abstract available
    
    
    October 2017
43. HSU PY, Wu VS, Kanaya N, Petrossian K, et al
    Dual mTOR Kinases MLN0128 Inhibitor Sensitizes HR+/HER2+ Breast Cancer Patient-derived Xenografts to Trastuzumab or Fulvestrant.
    Clin Cancer Res. 2017 Oct 27. pii: clincanres.1983.2017.
    PubMed     Text format     Abstract available
    
    
    
44. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    PubMed     Text format     Abstract available
    
    
    
45. YU Z, He S, Wang D, Patel HK, et al
    Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
46. LUNDBERG A, Lindstrom LS, Harrell JC, Falato C, et al
    Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.1535.2017.
    PubMed     Text format     Abstract available
    
    
    
47. TOBIN NP, Lundberg A, Lindstrom LS, Harrell JC, et al
    PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.2301.2017.
    PubMed     Text format     Abstract available
    
    
    
48. DOOSTAN I, Karakas C, Kohansal M, Low KH, et al
    Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
    Clin Cancer Res. 2017 Sep 25. pii: clincanres.1544.2017.
    PubMed     Text format     Abstract available
    
    
    
49. ZHANG Y, Schroeder BE, Jerevall PL, Ly A, et al
    A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1688.2017.
    PubMed     Text format     Abstract available
    
    
    
50. DIOT G, Metz S, Noske A, Liapis E, et al
    Multi-Spectral Optoacoustic Tomography (MSOT) of human breast cancer.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.3200.2016.
    PubMed     Text format     Abstract available
    
    
    
51. MA CX, Suman V, Goetz MP, Northfelt DW, et al
    A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1260.2017.
    PubMed     Text format     Abstract available
    
    
    August 2017
52. SABBAGHI M, Gil-Gomez G, Guardia C, Servitja S, et al
    Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.
    Clin Cancer Res. 2017 Aug 18. pii: clincanres.0696.2017.
    PubMed     Text format     Abstract available
    
    
    
53. EMENS LA
    Breast Cancer Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Aug 11. pii: clincanres.3001.2017.
    PubMed     Text format     Abstract available
    
    
    
54. VAN DER VELDEN BHM, Elias SG, Bismeijer T, Loo CE, et al
    Complementary value of contralateral parenchymal enhancement on DCE-MRI to prognostic models and molecular assays in high-risk ER+HER2- breast cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0176.2017.
    PubMed     Text format     Abstract available
    
    
    July 2017
55. FORMISANO L, Stauffer KM, Young CD, Bhola NE, et al
    Association of FGFR1 with ERalphamaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1232.2017.
    PubMed     Text format     Abstract available
    
    
    
56. SUN J, Meng H, Yao L, Lv M, et al
    Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.3227.2016.
    PubMed     Text format     Abstract available
    
    
    
57. UEDA S, Saeki T, Osaki A, Yamane T, et al
    Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: Multimodal functional imaging and multiplex cytokine analysis.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0874.2017.
    PubMed     Text format     Abstract available
    
    
    
58. RIETHDORF S, Muller V, Loibl S, Nekljudova V, et al
    Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0255.2017.
    PubMed     Text format     Abstract available
    
    
    
59. MA CX, Bose R, Gao F, Freedman RA, et al
    Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0900.2017.
    PubMed     Text format     Abstract available
    
    
    June 2017
60. KENNY T, Schmidt H, Adelson K, Hoshida Y, et al
    Patient-derived interstitial fluids and predisposition to aggressive sporadic breast cancer through collagen remodeling and inactivation of p53.
    Clin Cancer Res. 2017 Jun 19. pii: clincanres.0342.2017.
    PubMed     Text format     Abstract available
    
    
    
61. TURNER NC, Asghar U, Barr AR, Cutts R, et al
    Single-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancer.
    Clin Cancer Res. 2017 Jun 12. pii: clincanres.0369.2017.
    PubMed     Text format     Abstract available
    
    
    
62. REEDER-HAYES KE, Anderson BO
    Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.
    Clin Cancer Res. 2017;23:2655-2664.
    PubMed     Text format     Abstract available
    
    
    
63. FREEDMAN RA, Partridge AH
    Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer.
    Clin Cancer Res. 2017;23:2647-2654.
    PubMed     Text format     Abstract available
    
    
    
64. VONDERHEIDE RH, Domchek SM, Clark AS
    Immunotherapy for Breast Cancer: What Are We Missing?
    Clin Cancer Res. 2017;23:2640-2646.
    PubMed     Text format     Abstract available
    
    
    
65. YATES LR, Desmedt C
    Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.
    Clin Cancer Res. 2017;23:2630-2639.
    PubMed     Text format     Abstract available
    
    
    
66. NIK-ZAINAL S, Morganella S
    Mutational Signatures in Breast Cancer: The Problem at the DNA Level.
    Clin Cancer Res. 2017;23:2617-2629.
    PubMed     Text format     Abstract available
    
    
    
67. PARTRIDGE AH, Carey LA
    Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?
    Clin Cancer Res. 2017;23:2611-2616.
    PubMed     Text format     Abstract available
    
    
    May 2017
68. SCHOTT AF, Goldstein L, Cristofanilli M, Ruffini PA, et al
    Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC).
    Clin Cancer Res. 2017 May 24. pii: clincanres.2748.2016.
    PubMed     Text format     Abstract available
    
    
    
69. REINHOLZ MM, Chen B, Dueck AC, Tenner K, et al
    IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
    Clin Cancer Res. 2017 May 22. doi: 10.1158/1078-0432.CCR-15-0574.
    PubMed     Text format     Abstract available
    
    
    
70. DICKLER MN, Tolaney S, Rugo HS, Cortes J, et al
    MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.
    Clin Cancer Res. 2017 May 22. pii: clincanres.0754.2017.
    PubMed     Text format     Abstract available
    
    
    
71. SHAASHUA L, Shabat-Simon M, Haldar R, Matzner P, et al
    Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0152.2017.
    PubMed     Text format     Abstract available
    
    
    
72. SILWAL-PANDIT L, Nord S, von der Lippe Gythfeldt H, Moller EK, et al
    The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer.
    Clin Cancer Res. 2017 May 9. pii: clincanres.0160.2017.
    PubMed     Text format     Abstract available
    
    
    
73. XU X, De Angelis C, Burke KA, Nardone A, et al
    HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.
    Clin Cancer Res. 2017 May 9. pii: clincanres.2191.2016.
    PubMed     Text format     Abstract available
    
    
    
74. BIHANI T, Patel HK, Arlt H, Tao N, et al
    Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti-tumor activity in multiple ER+ breast cancer patient-derived xenograft models.
    Clin Cancer Res. 2017 May 4. pii: clincanres.2561.2016.
    PubMed     Text format     Abstract available
    
    
    
75. TORRES-ADORNO AM, Lee J, Kogawa T, Ordentlich P, et al
    Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer.
    Clin Cancer Res. 2017 May 2. pii: clincanres.2622.2016.
    PubMed     Text format     Abstract available
    
    
    April 2017
76. PIEROBON M, Ramos C, Wong S, Hodge KA, et al
    Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2656.2016.
    PubMed     Text format     Abstract available
    
    
    
77. WEERTS MJA, Hollestelle A, Sieuwerts AM, Foekens JA, et al
    Low Tumor Mitochondrial DNA Content is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-based Chemotherapy.
    Clin Cancer Res. 2017 Apr 18. pii: clincanres.0032.2017.
    PubMed     Text format     Abstract available
    
    
    
78. ASSADIPOUR Y, Zacharakis N, Crystal JS, Prickett TD, et al
    Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2017 Apr 4. pii: clincanres.1423.2016.
    PubMed     Text format     Abstract available
    
    
    March 2017
79. SOMLO G, Frankel P, Arun B, Ma CX, et al
    Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 29. pii: clincanres.2714.2016.
    PubMed     Text format     Abstract available
    
    
    
80. PITRODA S, Bao R, Andrade J, Weichselbaum RR, et al
    Low Recombination Proficiency Score (RPS) predicts heightened sensitivity to DNA-damaging chemotherapy in breast cancer.
    Clin Cancer Res. 2017 Mar 24. pii: clincanres.2845.2016.
    PubMed     Text format     Abstract available
    
    
    
81. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Text format     Abstract available
    
    
    
82. SCHWARTZBERG LS, Yardley D, Elias A, Patel M, et al
    A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2339.2016.
    PubMed     Text format     Abstract available
    
    
    
83. JOVANOVIC B, Mayer IA, Mayer EL, Abramson VG, et al
    A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC).
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3055.2016.
    PubMed     Text format     Abstract available
    
    
    
84. MA CX, Gao F, Luo J, Northfelt DW, et al
    NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer.
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3206.2016.
    PubMed     Text format     Abstract available
    
    
    February 2017
85. HUSING A, Fortner RT, Kuhn T, Overvad K, et al
    Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: Results from the EPIC cohort.
    Clin Cancer Res. 2017 Feb 28. pii: clincanres.3011.2016.
    PubMed     Text format     Abstract available
    
    
    January 2017
86. SHACHAR SS, Deal AM, Weinberg M, Williams GR, et al
    Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane Based Chemotherapy for Early Stage Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2266.2016.
    PubMed     Text format     Abstract available
    
    
    
87. SINGER CF, Tan YY, Fitzal F, Steger GG, et al
    Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2373.2016.
    PubMed     Text format     Abstract available
    
    
    
88. DEGNIM AC, Hoskin TL, Arshad M, Frost MH, et al
    Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.
    Clin Cancer Res. 2017 Jan 26. pii: clincanres.2026.2016.
    PubMed     Text format     Abstract available
    
    
    
89. 
    Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90.
    Clin Cancer Res. 2017;23:612.
    PubMed     Text format    
    
    
    
90. AFGHAHI A, Timms KM, Vinayak S, Jensen KC, et al
    Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.2174.2016.
    PubMed     Text format     Abstract available
    
    
    
91. HART CD, Vignoli A, Tenori L, Uy GL, et al
    Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
    Clin Cancer Res. 2017 Jan 12. doi: 10.1158/1078-0432.CCR-16-1153.
    PubMed     Text format     Abstract available
    
    
    
92. WU J, Cui Y, Sun X, Cao G, et al
    Unsupervised clustering of quantitative image phenotypes reveals breast cancer subtypes with distinct prognoses and molecular pathways.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2415.2016.
    PubMed     Text format     Abstract available
    
    
    
93. CARDILLO TM, Sharkey RM, Rossi DL, Arrojo R, et al
    Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP-inhibitors in BRCA1/2-wild-type triple-negative breast cancer.
    Clin Cancer Res. 2017 Jan 9. pii: clincanres.2401.2016.
    PubMed     Text format     Abstract available
    
    
    
94. MOULDER-THOMPSON S, Borges VF, Baetz TD, Mcspadden T, et al
    Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).
    Clin Cancer Res. 2017 Jan 4. pii: clincanres.1496.2016.
    PubMed     Text format     Abstract available
    
    
    December 2016
95. LIU Y, Burness ML, Martin-Trevino R, Guy J, et al
    RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2016 Dec 29. doi: 10.1158/1078-0432.CCR-15-1348.
    PubMed     Text format     Abstract available
    
    
    
96. HUMPHRIES MP, Sundara Rajan S, Droop A, Suleman C, et al
    A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.1952.2016.
    PubMed     Text format     Abstract available
    
    
    
97. CONNOLLY R, Li H, Jankowitz RC, Zhang Z, et al
    Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1729.2016.
    PubMed     Text format     Abstract available
    
    
    
98. JANKOWITZ RC, Oesterreich S, Lee AV, Davidson NE, et al
    New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and other Targeted Therapies.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.0591.2016.
    PubMed     Text format     Abstract available
    
    
    
99. LECONET W, Chentouf M, Du Manoir S, Chevalier C, et al
    Therapeutic activity of anti-AXL antibody against triple-negative breast cancer Patient Derived Xenografts and metastasis.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.1316.2016.
    PubMed     Text format     Abstract available
    
    
    November 2016
100. HOSFORD SR, Dillon LM, Bouley SJ, Rosati R, et al
     Combined inhibition of both p110alpha and p110beta isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER+ breast cancer.
     Clin Cancer Res. 2016 Nov 30. pii: clincanres.2764.2015.
     PubMed     Text format     Abstract available
     
     
     
101. PRAT A, Lluch A, Turnbull AK, Dunbier AK, et al
     A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
     Clin Cancer Res. 2016 Nov 30. pii: clincanres.2092.2016.
     PubMed     Text format     Abstract available
     
     
     
102. HUNT KK, Karakas C, Ha MJ, Biernacka A, et al
     Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
     Clin Cancer Res. 2016 Nov 23. pii: clincanres.2217.2016.
     PubMed     Text format     Abstract available
     
     
     
103. LAMBERTS LE, Koch M, de Jong JS, Adams A, et al
     Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study.
     Clin Cancer Res. 2016 Nov 9. pii: clincanres.0437.2016.
     PubMed     Text format     Abstract available
     
     
     
104. BOZOVIC-SPASOJEVIC I, Zardavas D, Brohee S, Ameye L, et al
     The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.
     Clin Cancer Res. 2016 Nov 9. pii: clincanres.0979.2016.
     PubMed     Text format     Abstract available
     
     
     
105. ELEBRO K, Borgquist S, Rosendahl AH, Markkula A, et al
     High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients - results from a population-based breast cancer cohort.
     Clin Cancer Res. 2016 Nov 3. pii: clincanres.1095.2016.
     PubMed     Text format     Abstract available
     
     
     
106. BRAND JS, Hedayati E, Humphreys K, Ludvigsson JF, et al
     Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.
     Clin Cancer Res. 2016;22:5249-5255.
     PubMed     Text format     Abstract available
     
     
     October 2016
107. CHAN N, Willis A, Kornhauser N, Ward MM, et al
     Influencing the tumor microenvironment: Phase 2 Study of Copper depletion with tetrathiomolybdate in high risk breast cancer and preclinical models of lung metastases.
     Clin Cancer Res. 2016 Oct 21. pii: clincanres.1326.2016.
     PubMed     Text format     Abstract available
     
     
     
108. ZEMBUTSU H, Nakamura S, Akashi ST, Kuwayama T, et al
     Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer; a Prospective Multicenter Study.
     Clin Cancer Res. 2016 Oct 19. pii: clincanres.1779.2016.
     PubMed     Text format     Abstract available
     
     
     
109. BRECHBUHL HM, Finlay-Schultz J, Yamamoto T, Gillen A, et al
     Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen.
     Clin Cancer Res. 2016 Oct 4. pii: clincanres.2851.2015.
     PubMed     Text format     Abstract available
     
     
     
110. MERCOGLIANO MF, De Martino M, Venturutti L, Rivas MA, et al
     TNFalpha-induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
     Clin Cancer Res. 2016 Oct 3. pii: clincanres.0970.2016.
     PubMed     Text format     Abstract available
     
     
     
111. ZUO WJ, Jiang YZ, Wang YJ, Xu XE, et al
     Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.
     Clin Cancer Res. 2016;22:4859-4869.
     PubMed     Text format     Abstract available
     
     
     September 2016
112. RENNERT G, Pinchev M, Gronich N, Saliba W, et al
     Oral bisphosphonates and improved survival of breast cancer.
     Clin Cancer Res. 2016 Sep 28. pii: clincanres.0547.2016.
     PubMed     Text format     Abstract available
     
     
     
113. 
     Correction: Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C Alpha.
     Clin Cancer Res. 2016;22:4756.
     PubMed     Text format    
     
     
     
114. LIPS EH, Debipersad R, Scheerman CE, Mulder L, et al
     BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
     Clin Cancer Res. 2016 Sep 12. pii: clincanres.0198.2016.
     PubMed     Text format     Abstract available
     
     
     
115. NIELSEN TO, Jensen MB, Burugu S, Gao D, et al
     High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial.
     Clin Cancer Res. 2016 Sep 6. pii: clincanres.1278.2016.
     PubMed     Text format     Abstract available
     
     
     
116. VON WAHLDE MK, Timms KM, Chagpar AB, Wali VB, et al
     Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
     Clin Cancer Res. 2016 Sep 6. pii: clincanres.0889.2016.
     PubMed     Text format     Abstract available
     
     
     
117. 
     Correction: Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
     Clin Cancer Res. 2016;22:4536.
     PubMed     Text format    
     
     
     
118. QUINTELA-FANDINO M, Lluch A, Manso LM, Calvo I, et al
     18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial.
     Clin Cancer Res. 2016 Sep 1. pii: clincanres.0738.2016.
     PubMed     Text format     Abstract available
     
     
     August 2016
119. MCARTHUR HL, Diab A, Page DB, Yuan J, et al
     A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling.
     Clin Cancer Res. 2016 Aug 26. pii: clincanres.0190.2016.
     PubMed     Text format     Abstract available
     
     
     
120. BRUFSKY AM, Davidson NE
     Multi-parametric genomic assays for breast cancer: Time for the next generation?
     Clin Cancer Res. 2016 Aug 12. pii: clincanres.1513.2016.
     PubMed     Text format     Abstract available
     
     
     
121. PARSONS HA, Beaver JA, Cimino-Mathews A, Ali SM, et al
     Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer.
     Clin Cancer Res. 2016 Aug 3. pii: clincanres.1543.2016.
     PubMed     Text format     Abstract available
     
     
     
122. STRULOV SHACHAR S, Deal AM, Weinberg M, Nyrop KA, et al
     Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane Based Chemotherapy.
     Clin Cancer Res. 2016 Aug 3. pii: clincanres.0940.2016.
     PubMed     Text format     Abstract available
     
     
     July 2016
123. SAMAEEKIA R, Adorno-Cruz V, Bockhorn J, Chang YF, et al
     MicroRNA-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway.
     Clin Cancer Res. 2016 Jul 19. pii: clincanres.0943.2016.
     PubMed     Text format     Abstract available
     
     
     
124. AL-AZHRI J, Zhang Y, Bshara W, Zirpoli GR, et al
     Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.
     Clin Cancer Res. 2016 Jul 12. pii: clincanres.0075.2016.
     PubMed     Text format     Abstract available
     
     
     
125. WALKER AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, et al
     FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
     Clin Cancer Res. 2016 Jul 12. pii: clincanres.0493.2016.
     PubMed     Text format     Abstract available
     
     
     June 2016
126. KURLAND BF, Peterson LM, Lee JH, Schubert EK, et al
     Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
     Clin Cancer Res. 2016 Jun 24. pii: clincanres.0362.2016.
     PubMed     Text format     Abstract available
     
     
     
127. SHAW JA, Guttery DS, Hills A, Fernandez-Garcia D, et al
     Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts.
     Clin Cancer Res. 2016 Jun 22. pii: clincanres.0825.2016.
     PubMed     Text format     Abstract available
     
     
     
128. STOVER DG, Coloff JL, Barry WT, Brugge JS, et al
     The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
     Clin Cancer Res. 2016 Jun 21. pii: clincanres.0471.2016.
     PubMed     Text format     Abstract available
     
     
     
129. PATEL H, Abduljabbar R, Lai CF, Periyasamy M, et al
     CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer.
     Clin Cancer Res. 2016 Jun 14. pii: clincanres.1104.2015.
     PubMed     Text format     Abstract available
     
     
     
130. SHARMA P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, et al
     Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts.
     Clin Cancer Res. 2016 Jun 14. pii: clincanres.0162.2016.
     PubMed     Text format     Abstract available
     
     
     
131. LI W, O'Shaughnessy JA, Hayes DF, Campone M, et al
     Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
     Clin Cancer Res. 2016 Jun 7. pii: clincanres.2452.2015.
     PubMed     Text format     Abstract available
     
     
     
132. WANG ZQ, Milne K, Derocher H, Webb JR, et al
     CD103 and Intratumoral Immune Response in Breast Cancer.
     Clin Cancer Res. 2016 Jun 7. pii: clincanres.0732.2016.
     PubMed     Text format     Abstract available
     
     
     
133. ALVES CL, Elias D, Lyng MB, Bak M, et al
     High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer.
     Clin Cancer Res. 2016 Jun 1. pii: clincanres.1984.2015.
     PubMed     Text format     Abstract available
     
     
     
134. SESTAK I, Zhang Y, Schroeder BE, Schnabel CA, et al
     Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer.
     Clin Cancer Res. 2016 Jun 1. pii: clincanres.0155.2016.
     PubMed     Text format     Abstract available
     
     
     
135. 
     Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer.
     Clin Cancer Res. 2016;22:2825.
     PubMed     Text format    
     
     
     May 2016
136. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
     Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
     Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
     PubMed     Text format     Abstract available
     
     
     
137. SPEERS C, Zhao SG, Kothari V, Santola A, et al
     Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer.
     Clin Cancer Res. 2016 May 25. pii: clincanres.2711.2015.
     PubMed     Text format     Abstract available
     
     
     
138. INGOLD HEPPNER B, Untch M, Denkert C, Pfitzner BM, et al
     Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2-positive breast cancer.
     Clin Cancer Res. 2016 May 17. pii: clincanres.2338.2015.
     PubMed     Text format     Abstract available
     
     
     
139. JESELSOHN R, Barry WT, Migliaccio I, Biagioni C, et al
     TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer.
     Clin Cancer Res. 2016 May 16. pii: clincanres.0148.2016.
     PubMed     Text format     Abstract available
     
     
     
140. GYANCHANDANI R, Lin Y, Lin HM, Cooper KL, et al
     Intra-tumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer.
     Clin Cancer Res. 2016 May 16. pii: clincanres.2889.2015.
     PubMed     Text format     Abstract available
     
     
     
141. KLINTMAN M, Buus R, Cheang MC, Sheri A, et al
     Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
     Clin Cancer Res. 2016;22:2405-16.
     PubMed     Text format     Abstract available
     
     
     
142. DENNISON JB, Shahmoradgoli M, Liu W, Ju Z, et al
     High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype.
     Clin Cancer Res. 2016 May 12. pii: clincanres.0171.2016.
     PubMed     Text format     Abstract available
     
     
     
143. MITRI Z, Nanda R, Blackwell K, Costelloe CM, et al
     TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
     Clin Cancer Res. 2016 May 10. pii: clincanres.2845.2015.
     PubMed     Text format     Abstract available
     
     
     
144. GILANI R, Phadke S, Bao LW, Lachacz E, et al
     UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer.
     Clin Cancer Res. 2016 May 6. pii: clincanres.2158.2015.
     PubMed     Text format     Abstract available
     
     
     February 2016
145. PODO F, Santoro F, Di Leo G, Manoukian S, et al
     Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
     Clin Cancer Res. 2016;22:895-904.
     PubMed     Text format     Abstract available
     
     
     
146. SAMENI M, Tovar EA, Essenburg CJ, Chalasani A, et al
     Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
     Clin Cancer Res. 2016;22:923-34.
     PubMed     Text format     Abstract available
     
     
     
147. CHU D, Paoletti C, Gersch C, VanDenBerg DA, et al
     ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
     Clin Cancer Res. 2016;22:993-9.
     PubMed     Text format     Abstract available
     
     
     
148. ABDEL-FATAH TM, McArdle SE, Agarwal D, Moseley PM, et al
     HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
     Clin Cancer Res. 2016;22:905-14.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: